poisar

Stocks · News reference

Ensysce Biosciences Completes Enrollment In Final Stage Of PF614-MPAR-102 Clinical Study

BenzingaBenzinga Newsdesk

~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~SAN DIEGO, CA / ACCESS Newswire / August 31, 2026 / Ensysce Biosciences, Inc.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Fiscal.ai

    Ensysce Biosciences Announces CEO Transition

    Ensysce Biosciences announced that CEO Lynn Kirkpatrick will transition to the role of Chief Operating Officer, with President James Morrisson set to assume the CEO position following the company's annual meeting on December 14, 2026.